We are live on ! Find out more
NVO icon

Novo Nordisk

461 hedge funds and large institutions have $8.33B invested in Novo Nordisk in 2014 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 150 increasing their positions, 179 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

77% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 31

65% more funds holding in top 10

Funds holding in top 10: 17 → 28 (+11)

34% more capital inflows, than outflows

Capital inflows: $646M | Capital outflows: $482M

7% more funds holding

Funds holding: 432 → 461 (+29)

0.15% more ownership

Funds ownership: 7.86% → 8% (+0.15%)

16% less repeat investments, than reductions

Existing positions increased: 150 | Existing positions reduced: 179

53% less call options, than puts

Call options by funds: $8.57M | Put options by funds: $18.2M

Holders
461
Holders Change
+29
Holders Change %
+6.71%
% of All Funds
13.27%
Holding in Top 10
28
Holding in Top 10 Change
+11
Holding in Top 10 Change %
+64.71%
% of All Funds
0.81%
New
55
Increased
150
Reduced
179
Closed
31
Calls
$8.57​M
Puts
$18.2​M
Net Calls
-⁠$9.6​M
Net Calls Change
-⁠$7.22​M

NVO Hedge Fund Activity: Q1 2014 in Review

461 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2014, worth a combined $8.33B — up 25% from $6.64B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new NVO positions and 31 closed out — a net gain of 24 holders — while 150 added to existing stakes and 179 trimmed.

The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $166M. The largest seller was WCM Investment Management, cutting an estimated $108M.

  • 461 institutional investors held Novo Nordisk (NVO) as of Q1 2014, up from 432 in Q4 2013.
  • Funds reported $8.33B of Novo Nordisk stock for Q1 2014, up 25% quarter-over-quarter.
  • 55 funds opened new Novo Nordisk positions in Q1 2014 and 31 closed out, a net change of +24 holders.
  • The largest Novo Nordisk buyer in Q1 2014 was Loomis, Sayles & Company, an estimated $166M added.
  • The largest Novo Nordisk seller in Q1 2014 was WCM Investment Management, an estimated $108M sold.

Based on aggregated 13F filings for Q1 2014.